Basic Information
| LncRNA/CircRNA Name | LINC00152 |
| Synonyms | CYTOR, C2orf59, LINC00152, NCRNA00152 |
| Region | GRCh38_2:87454781-87636740 |
| Ensemble | ENSG00000222041 |
| Refseq | NR_024204 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | RNA-seq, qPCR etc. |
| Sample | glioma tissues |
| Expression Pattern | up-regulated |
| Function Description | We validated the altered expression of three lncRNAs, LINC00152, TUNAR, and LINC01476. LINC00152 was found to have 3-fold higher expression in tumor tissue relative to normal brain tissue. TUNAR and LINC01476, were found to have 12-fold and nearly 100-fold higher expression in normal brain tissue compared to GBM tissue, respectively. |
| Pubmed ID | 27923049 |
| Year | 2016 |
| Title | Expression of lncRNAs in Low-Grade Gliomas and Glioblastoma Multiforme: An In Silico Analysis. |
External Links
| Links for LINC00152 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |